Mastering the use of cellular barcoding to explore cancer heterogeneity

A Serrano; J Berthelet; SH Naik; D Merino

Journal article

Mastering the use of cellular barcoding to explore cancer heterogeneity

A Serrano, J Berthelet, SH Naik, D Merino

Nature Reviews Cancer | NATURE PORTFOLIO | Published : 2022

DOI: 10.1038/s41568-022-00500-2

Abstract

Tumours are often composed of a multitude of malignant clones that are genomically unique, and only a few of them may have the ability to escape cancer therapy and grow as symptomatic lesions. As a result, tumours with a large degree of genomic diversity have a higher chance of leading to patient death. However, clonal fate can be driven by non-genomic features. In this context, new technologies are emerging not only to track the spatiotemporal fate of individual cells and their progeny but also to study their molecular features using various omics analysis. In particular, the recent development of cellular barcoding facilitates the labelling of tens to millions of cancer clones and enables ..

View full abstract

University of Melbourne Researchers

Antonin Serrano Author

Shalin Naik Author

Related Projects (1)

IDENTIFICATION OF HAEMATOPOIETIC STEM AND PROGENITOR CELL SUBPOPULATIONS

We want to dissect the machinery underlying how each and every individual stem and progenitor cell generates the different blood cell types...

Grants

Awarded by Victorian Cancer Agency

Funding Acknowledgements

The authors acknowledge F. El-Saafin and S. Gadipally for their constructive feedback, and T. Weber for useful discussions. A.S. is supported by the Melbourne Research Scholarship. D.M. is supported by Cancer Council Victoria, the Love Your Sister Foundation, the NBCF (Investigator Initiated Research Scheme grant IIRS-19-082), Susan G. Komen and Cancer Australia (CCR19606878), the Victorian Cancer Agency Mid-Career Research Fellowship (MCRF21011) and the Australian National Health and Medical Research Council (Grant 2012196). S.H.N. is supported by the Australian National Health and Medical Research Council (Grants 1062820, 1100033, 1101378, 1124812 and 1145184). The authors and the Olivia Newton-John Cancer Research Institute gratefully acknowledge the generous support of the Love Your Sister Foundation and the contribution of the Victorian Government acting through the Victorian Cancer Agency. The contents of the published material are solely the responsibility of the individual authors and do not reflect the views of Cancer Australia or other funding agencies.